{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:41:43Z","timestamp":1790800903579,"version":"4.1.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T00:00:00Z","timestamp":1540857600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Alios Biopharma"},{"name":"Johnson and Johnson Company"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,1]]},"DOI":"10.1093\/jac\/dky415","type":"journal-article","created":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T15:18:06Z","timestamp":1539962286000},"page":"442-452","source":"Crossref","is-referenced-by-count":38,"title":["Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humans"],"prefix":"10.1093","volume":"74","author":[{"given":"Kashyap","family":"Patel","sequence":"first","affiliation":[{"name":"d3 Medicine, A Certara Company, Parsippany, NJ, USA"},{"name":"Centre for Medicine Use and Safety, Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl M","family":"Kirkpatrick","sequence":"additional","affiliation":[{"name":"Centre for Medicine Use and Safety, Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A","family":"Nieforth","sequence":"additional","affiliation":[{"name":"d3 Medicine, A Certara Company, Parsippany, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushmita","family":"Chanda","sequence":"additional","affiliation":[{"name":"Alios BioPharma Inc, a Janssen Pharmaceutical Company of Johnson and Johnson, South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Alios BioPharma Inc, a Janssen Pharmaceutical Company of Johnson and Johnson, South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"McClure","sequence":"additional","affiliation":[{"name":"Alios BioPharma Inc, a Janssen Pharmaceutical Company of Johnson and Johnson, South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Fry","sequence":"additional","affiliation":[{"name":"Alios BioPharma Inc, a Janssen Pharmaceutical Company of Johnson and Johnson, South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian A","family":"Symons","sequence":"additional","affiliation":[{"name":"Alios BioPharma Inc, a Janssen Pharmaceutical Company of Johnson and Johnson, South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence M","family":"Blatt","sequence":"additional","affiliation":[{"name":"Alios BioPharma Inc, a Janssen Pharmaceutical Company of Johnson and Johnson, South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Beigelman","sequence":"additional","affiliation":[{"name":"Alios BioPharma Inc, a Janssen Pharmaceutical Company of Johnson and Johnson, South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P","family":"DeVincenzo","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics and Microbiology, Immunology and Biochemistry, University of Tennessee Center for Health Sciences, and Children\u2019s Foundation Research Institute at LeBonheur Children\u2019s Hospital, Memphis, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dymphy R","family":"Huntjens","sequence":"additional","affiliation":[{"name":"Janssen R&D, Janssen Pharmaceutica NV, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick F","family":"Smith","sequence":"additional","affiliation":[{"name":"d3 Medicine, A Certara Company, Parsippany, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,10,29]]},"reference":[{"key":"key\n\t\t\t\t2019012509155080200_dky415-B1","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1001\/jama.282.15.1440","article-title":"Bronchiolitis-associated hospitalizations among US children, 1980-1996","volume":"282","author":"Shay","year":"1999","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jama.289.2.179","article-title":"Mortality associated with influenza and respiratory syncytial virus in the United States","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B3","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study","volume":"390","author":"Shi","year":"2017","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B4","first-page":"543.","article-title":"Risk of primary infection and reinfection with respiratory syncytial virus","volume":"140","author":"Glezen","year":"1986","journal-title":"Am J Dis Child"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B5","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1067\/S0022-3476(03)00510-9","article-title":"Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000","volume":"143","author":"Leader","year":"2003","journal-title":"J Pediatr"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B6","doi-asserted-by":"crossref","first-page":"9139537.","DOI":"10.1155\/2016\/9139537","article-title":"Management of respiratory syncytial virus bronchiolitis: 2015 survey of members of the European Society for Paediatric Infectious Diseases","volume":"2016","author":"Carande","year":"2016","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B7","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/00006454-200008000-00032","article-title":"Therapy of respiratory syncytial virus infection","volume":"19","author":"DeVincenzo","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B8","doi-asserted-by":"crossref","first-page":"e620","DOI":"10.1542\/peds.2014-1666","article-title":"American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection","volume":"134","year":"2014","journal-title":"Pediatrics"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B9","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1542\/peds.2004-0959","article-title":"Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program","volume":"114","author":"Wegner","year":"2004","journal-title":"Pediatrics"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B10","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMoa1413275","article-title":"Activity of oral ALS-008176 in a respiratory syncytial virus challenge study","volume":"373","author":"DeVincenzo","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1021\/acschembio.6b00788","article-title":"Activation pathway of a nucleoside analog inhibiting respiratory syncytial virus polymerase","volume":"12","author":"Jordan","year":"2017","journal-title":"ACS Chem Biol"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B12","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1021\/jm5017279","article-title":"Discovery of 4\u2032-chloromethyl-2\u2032-deoxy-3\u2032, 5\u2032-di-O-isobutyryl-2\u2032-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection","volume":"58","author":"Wang","year":"2015","journal-title":"J Med Chem"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B13","doi-asserted-by":"crossref","first-page":"e1004995.","DOI":"10.1371\/journal.ppat.1004995","article-title":"Molecular basis for the selective inhibition of respiratory syncytial virus rna polymerase by 2\u2032-fluoro-4\u2032-chloromethyl-cytidine triphosphate","volume":"11","author":"Deval","year":"2015","journal-title":"PLoS Pathog"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B14","doi-asserted-by":"crossref","first-page":"7590","DOI":"10.1128\/JVI.01623-05","article-title":"Kinetics of influenza A virus infection in humans","volume":"80","author":"Baccam","year":"2006","journal-title":"J Virol"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B15","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1128\/JVI.01318-10","article-title":"Population modeling of influenza A\/H1N1 virus kinetics and symptom dynamics","volume":"85","author":"Canini","year":"2011","journal-title":"J Virol"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B16","doi-asserted-by":"crossref","first-page":"5388","DOI":"10.1128\/AAC.00069-15","article-title":"A drug-disease model describing the effect of oseltamivir neuraminidase inhibition on influenza virus progression","volume":"59","author":"Kamal","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B17","volume-title":"The Ethical Conduct of Research Involving Children","author":"Field","year":"2004"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10928-014-9363-3","article-title":"Viral kinetic modeling: state of the art","volume":"41","author":"Canini","year":"2014","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.tips.2008.01.007","article-title":"Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research","volume":"29","author":"Danhof","year":"2008","journal-title":"Trends Pharmacol Sci"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B20","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1128\/JCM.43.5.2356-2362.2005","article-title":"Comparison of a real-time reverse transcriptase PCR assay and a culture technique for quantitative assessment of viral load in children naturally infected with respiratory syncytial virus","volume":"43","author":"Perkins","year":"2005","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B21","author":"Kassir","year":"2013"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B22","author":"Pharsight","year":"2013"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B23","doi-asserted-by":"crossref","first-page":"567589","DOI":"10.1155\/2015\/567589","article-title":"Assessing uncertainty in A2 respiratory syncytial virus viral dynamics","volume":"2015","author":"Gonzalez-Parra","year":"2015","journal-title":"Comput Math Methods Med"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B24","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1016\/j.ejps.2017.05.070","article-title":"A human challenge model for respiratory syncytial virus kinetics, the pharmacological effect of a novel fusion inhibitor, and the modelling of symptoms scores","volume":"109","author":"Korell","year":"2017","journal-title":"Eur J Pharm Sci"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/0022-1317-21-1-1","article-title":"Interferon bioassay: reduction in yield of myxovirus neuraminidases","volume":"21","author":"Sedmak","year":"1973","journal-title":"J Gen Virol"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0025-5564(93)90043-A","article-title":"Dynamics of HIV infection of CD4+ T cells","volume":"114","author":"Perelson","year":"1993","journal-title":"Math Biosci"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B27","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1023\/B:JOPA.0000012998.04442.1f","article-title":"Simultaneous vs. sequential analysis for population PK\/PD data I: best-case performance","volume":"30","author":"Zhang","year":"2003","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B28","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm Res"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B29","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1012299115260","article-title":"Ways to fit a PK model with some data below the quantification limit","volume":"28","author":"Beal","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B30","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B31","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cmpb.2007.12.002","article-title":"Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R","volume":"90","author":"Comets","year":"2008","journal-title":"Comput Methods Programs Biomed"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B32","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1126\/science.276.5309.122","article-title":"A general model for the origin of allometric scaling laws in biology","volume":"276","author":"West","year":"1997","journal-title":"Science"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B33","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/jcph.555","article-title":"Quantitative clinical pharmacology for size and age scaling in pediatric drug development: a systematic review","volume":"55","author":"Samant","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B34","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003088-199630050-00001","article-title":"A size standard for pharmacokinetics","volume":"30","author":"Holford","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B35","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1542\/peds.2014-1665","article-title":"Committee on Infectious Diseases and Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection","volume":"134","year":"2014","journal-title":"Pediatrics"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B36","doi-asserted-by":"crossref","first-page":"E7.","DOI":"10.1542\/peds.99.2.e7","article-title":"Twenty years of outpatient respiratory syncytial virus infection: a framework for vaccine efficacy trials","volume":"99","author":"Fisher","year":"1997","journal-title":"Pediatrics"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B37","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/00006454-199705000-00004","article-title":"Treatment of respiratory syncytial virus bronchiolitis: 1995 poll of members of the European Society for Paediatric Infectious Diseases","volume":"16","author":"Kimpen","year":"1997","journal-title":"Pediatric Infect Dis J"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B38","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(10)60206-1","article-title":"Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis","volume":"375","author":"Nair","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B39","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejps.2016.01.016","article-title":"Top-down and bottom-up modeling in system pharmacology to understand clinical efficacy: an example with NRTIs of HIV-1","volume":"94","author":"Duwal","year":"2016","journal-title":"Eur J Pharm Sci"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B40","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/bcp.13229","article-title":"Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics","volume":"83","author":"Kamal","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B41","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10928-012-9264-2","article-title":"Extension of NPDE for evaluation of nonlinear mixed effect models in presence of data below the quantification limit with applications to HIV dynamic model","volume":"39","author":"Nguyen","year":"2012","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B42","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1208\/s12248-009-9112-5","article-title":"Handling data below the limit of quantification in mixed effect models","volume":"11","author":"Bergstrand","year":"2009","journal-title":"AAPS J"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B43","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/jps.23574","article-title":"A pharmacokinetic standard for babies and adults","volume":"102","author":"Holford","year":"2013","journal-title":"J Pharm Sci"},{"key":"key\n\t\t\t\t2019012509155080200_dky415-B44","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00467-008-0997-5","article-title":"Human renal function maturation: a quantitative description using weight and postmenstrual age","volume":"24","author":"Rhodin","year":"2009","journal-title":"Pediatr Nephrol"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/2\/442\/27524662\/dky415.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,27]],"date-time":"2019-10-27T04:54:05Z","timestamp":1572152045000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/74\/2\/442\/5146523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,29]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,10,29]]},"published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dky415","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734318721.793588346","asserted-by":"object"}]},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2]]},"published":{"date-parts":[[2018,10,29]]}}}